Page last updated: 2024-11-07

muramylnac-ala-isogln-lys-tripeptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

muramylNAc-Ala-isoGln-Lys-tripeptide: Ala-Ala dipeptide is added to this tripeptide by MurF synthetase to make the peptidoglycan pentapeptide; often called muramyl tripeptide but that term is ambiguous, confused with other tripeptides of muramic acid; the phosphatidylethanolamine conjugate is sometimes used [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119512
MeSH IDM0107764

Synonyms (14)

Synonym
murnac-tripeptide
64374-58-9
2-[[4-[2-[2-(2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl)oxypropanoylamino]propanoylamino]-5-amino-5-oxopentanoyl]amino]-6-aminoheptanedioic acid
acmu-ala-iso-gln-2,2'-diaminopimelic acid
dl-lysine, n2-(n2-(n-(n-acetylmuramoyl)-l-alanyl)-d-alpha-glutaminyl)-6-carboxy-, erythro-
lysine, n-(n-acetylmuramoyl)-l-alanyl-d-alpha-glutaminyl-6-carboxy-, erythro-
ac-mur-l-ala-gamma-d-gln-meso-a(2)pm
n-(n-acetylmuramoyl)-l-alanyl-d-alpha-glutaminyl-6-carboxylysine,
n-acetylmuramyl-alanyl-isoglutaminyl-meso-2,2'-diaminopimelic acid
d-glutamine, n2-(n-(n-acetylmuramoyl)-l-alanyl)-n-(5-amino-1,5-dicarboxypentyl)-, (r*,s*)-
n-acetylmuramyl-l-alanyl-d-isoglutaminyl-l-lysine
muramylnac-ala-isogln-lys-tripeptide
DTXSID50982928
3-o-(1-{[1-({5-[(5-amino-1,5-dicarboxypentyl)imino]-1,5-dihydroxy-1-iminopentan-2-yl}imino)-1-hydroxypropan-2-yl]imino}-1-hydroxypropan-2-yl)-2-deoxy-2-[(1-hydroxyethylidene)amino]hexose

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A definite species variation was established with regard to the toxic nature of muramyl peptides."( Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously.
Brown, NO; Fidler, IJ; Hart, IR, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" The purpose of this study was 2-fold: (a) to determine whether doxorubicin (DOX) would enhance or interfere with the effect of muramyl dipeptide and lipopolysaccharide on canine monocyte activation as measured by an in vitro WEHI-164 cell cytotoxicity assay; and (b) to evaluate the in vivo effect of DOX alone and combined with liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) on monocyte activation and serum tumor necrosis factor activity."( In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Kurzman, ID; MacEwen, EG; Shi, F, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (38.30)18.7374
1990's20 (42.55)18.2507
2000's8 (17.02)29.6817
2010's1 (2.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.14 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (8.00%)5.53%
Reviews2 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (88.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]